SCHEMBL22952971

SCHEMBL22952971

Oc1ccc2c(c1O)Oc1cncc3c1C2CNC3

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.35
PARP1 P09874 1/20 0.34
DRD2 P14416 1/20 0.33
DRD1 P21728 1/20 0.33
CYP3A4 P08684 4/20 0.32
MAPK1 P28482 4/20 0.32
HSD17B10 Q99714 3/20 0.32
ALOX15 P16050 2/20 0.32
TSHR P16473 2/20 0.32
NFKB1 P19838 1/20 0.32
THPO P40225 1/20 0.32
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
CYP2D6 P10635 1/20 0.31
KDM4E B2RXH2 4/20 0.31
MAPT P10636 4/20 0.31
HPGD P15428 4/20 0.31
ALDH1A1 P00352 3/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29383649 0.84 HTR2A (0.46) HTR2APARP1DRD2DRD1CYP3A4
SCHEMBL6345215 0.84 HTR2A (0.46) HTR2APARP1DRD2DRD1CYP3A4
Bromide SCHEMBL3668719 0.82 HTR2A (0.45) HTR2APARP1DRD2DRD1CYP3A4
SCHEMBL22952979 0.81 DRD2 (0.37) DRD2DRD1
SCHEMBL22952974 0.81 DRD2 (0.30) DRD2DRD1
SCHEMBL22952976 0.79 HTR2A (0.33) HTR2APARP1DRD2DRD1CYP3A4
SCHEMBL22953388 0.76 HTR2A (0.43) HTR2APARP1DRD2DRD1CYP3A4
SCHEMBL22952977 0.76 DRD1 (0.33) HTR2APARP1DRD2DRD1CYP3A4
SCHEMBL22953341 0.75 PARP1 (0.43) PARP1DRD2DRD1CYP3A4MAPK1
SCHEMBL22952973 0.69 PARP1 (0.38) PARP1CYP3A4MAPK1HSD17B10ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021021922-A1 COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2021-02-04 WO disclosed